Erythrocyte membrane vesicles as drug delivery systems: A systematic review of preclinical studies on biodistribution and pharmacokinetics

Biomaterials Advances, Journal Year: 2025, Volume and Issue: 170, P. 214234 - 214234

Published: Feb. 14, 2025

This systematic review aims to summarize the development of erythrocyte membrane vesicles (EMVs) as drug delivery carriers, with a focus on elucidating their fate in terms biodistribution and pharmacokinetics preclinical studies. The PubMed database was systematically reviewed search for original peer-reviewed published studies use EMVs findings, following PRISMA guidelines. A total 142 articles matched selection criteria were included review. For each study, parameters extracted: type active pharmaceutical ingredient (API) encapsulated into EMVs, EMVs-API formulation method final particle size, surface modifications targeting, cell lines animal models used crucial treatment data, data finally, where applicable, about circulation time blood half-life. size did not vary significantly among different methods. complete list is provided. Circulation times half-life grouped per type. most commonly type, BALB/c mice, average EMV-API calculated be 10.4 h, all cases, up 10-fold increase observed compared that free API. Surface drastically change but improve target tissue accumulation. critical weaknesses analysed identified. Key points future are provided fill current knowledge gaps quality publications.

Language: Английский

Cryptotanshinone-loaded biomimetic pH-sensitive liposomes for the treatment of liver fibrosis

Journal of Drug Delivery Science and Technology, Journal Year: 2024, Volume and Issue: unknown, P. 106496 - 106496

Published: Dec. 1, 2024

Language: Английский